查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1836233

慢性难治性痛风市场，按治疗类别、按给药途径、按疾病负担、按合併症情况、按护理环境、按配销通路和按地区 - 行业分析、市场规模、市场份额和预测（2025 年至 2032 年）

Chronic Refractory Gout Market, By Therapy Class, By Route of Administration, By Disease Burden, By Comorbidity Profile, By Care Setting, By Distribution Channel, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 402 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年慢性难治性痛风市场规模价值 18.0425 亿美元，2025 年至 2032 年的复合年增长率为 10.23%。

慢性难治性痛风是一种严重的痛风类型，患者对标准降尿酸疗法反应不佳或无法耐受。其特征是持续高尿酸水平、频繁的疼痛发作以及痛风石形成，痛风石会损害关节和周围组织。这种疾病通常需要先进的治疗方法，例如基于尿酸酶的疗法或生物製剂，以及对合併症的全面管理，以减少併发症并改善生活品质。

慢性难治性痛风市场-市场动态

全球痛风负担加重，推动市场需求

全球痛风负担日益加重，推动了对先进治疗方案的需求。 2020年，全球估计有5,580万人患有痛风。肥胖和肾功能障碍是导致痛风致残的主要原因，其中高体重指数占痛风致残寿命年（YLD）的34.3%，肾功能障碍占11.8%。然而，这些合併症的漏诊往往会延误适当的治疗。

美国疾病管制与预防中心 (CDC) 报告称，超过七分之一的美国成年人患有慢性肾臟病。积极的一面是，针对肥胖的生活方式介入可以显着降低痛风的严重程度和进展。此外，改善痛风患者的慢性肾臟病 (CKD) 检测可以改善治疗效果，并有助于解决导致难治性痛风的关键潜在因素之一。

慢性难治性痛风市场-細項分析：

全球慢性难治性痛风市场根据治疗类别、给药途径、疾病负担、合併症概况、推进力、配销通路和地区进行细分。

根据治疗类别，市场分为四类：尿酸酶疗法、IL-1抑制剂、辅助抗发炎药物和新一代小分子药物。预计尿酸酶疗法将在预测期内占据主要市场份额。这种主导地位源于其独特的功效，即快速有效地降低对常规治疗无效患者的血清尿酸水平。

根据合併症情况，市场分为两类：肾功能损害和心血管/代谢疾病。其中，肾功能损害预计将占据主要市场份额。慢性肾臟病是痛风患者的常见併发症，限制了传统降尿酸药物的使用，并增加了对尿酸酶类药物等先进疗法的依赖。肾功能损害是治疗的最大挑战，推动了该患者群体对专业有效的治疗方案的需求日益增强。

慢性难治性痛风市场－地理洞察

北美癌症切片市场占据全球主导地位，由于疾病负担高且医疗基础设施完善，慢性难治性痛风领域也呈现类似的趋势。根据美国疾病管制与预防中心 (CDC) 的数据，美国近 920 万成年人患有痛风，约占成年人口的 3.9%。

其中相当一部分病例发展为慢性和难治性疾病，推动了对聚乙二醇重组尿酸酶等先进疗法的需求。美国食品药物管理局 (FDA) 已优先批准生物製剂和新型降尿酸药物，以满足难治性病例中尚未满足的需求。在欧洲，痛风的盛行率也引人注目，英国国家医疗服务体系 (NHS) 报告称，过去十年痛风相关住院人数急剧上升。同时，在亚太地区，日本厚生劳动省将痛风列为与生活方式疾病相关的日益严重的问题，这进一步扩大了治疗需求。

慢性难治性痛风市场-竞争格局：

不受控制的痛风病例日益增多，促使各公司改善治疗策略。竞争对手正专注于开发安全性更高、疗效更持久的生物製剂和基于尿酸酶的疗法。许多公司正在探索与免疫调节剂的联合疗法，以减少抗体形成并提高疗效。与研究机构、专科诊所和付款方的合作旨在扩大患者的治疗可及性。同时，各公司正在投资患者支援计画、输液服务和数位监测工具，以增强患者依从性并改善长期治疗效果。

目录

第一章：慢性难治性痛风市场概述

  • 研究范围
  • 市场估计年限

第 2 章：执行摘要

  • 市场片段
    • 慢性难治性痛风市场片段（依治疗类别）
    • 慢性难治性痛风市场依给药途径分类
    • 慢性难治性痛风市场片段（依疾病负担）
    • 慢性难治性痛风市场片段（依合併症概况）
    • 慢性难治性痛风市场片段（依护理环境）
    • 慢性难治性痛风市场片段（依配销通路）
    • 慢性难治性痛风市场（依国家）
    • 慢性难治性痛风市场（按地区）
  • 竞争洞察

第三章：慢性难治性痛风关键市场趋势

  • 慢性难治性痛风市场驱动因素
    • 市场驱动因素的影响分析
  • 慢性难治性痛风市场限制
    • 市场限制的影响分析
  • 慢性难治性痛风市场机会
  • 慢性难治性痛风市场未来趋势

第四章：慢性难治性痛风产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第五章：慢性难治性痛风市场：地缘政治紧张局势升级的影响

  • COVID-19 疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：慢性难治性痛风市场格局

  • 2023年慢性难治性痛风市占率分析
  • 按主要製造商分類的细分数据
    • 成熟玩家分析
    • 新兴企业分析

第七章：慢性难治性痛风市场－依治疗类型

  • 概述
    • 按治疗类别分類的细分份额分析
      • 尿酸酶疗法
      • IL-1抑制剂
      • 辅助抗发炎药
      • 新一代小分子

第 8 章：慢性难治性痛风市场 - 依给药途径

  • 概述
    • 按给药途径分類的细分市占率分析
    • 静脉
    • 皮下
    • 口服

慢性难治性痛风市场 - 按疾病负担

  • 概述
    • 按疾病负担分類的细分份额分析
    • 痛风石性CRG
    • 频繁爆发
    • 侵蚀/结构损坏

第九章：慢性难治性痛风市场－依合併症分类

  • 概述
    • 依合併症状况分析细分份额
    • 肾功能不全
    • 心血管/代谢疾病

第 10 章：慢性难治性痛风市场 - 按护理环境

  • 概述
    • 按护理环境分類的细分份额分析
    • 医院
    • 专科风湿病诊所
    • 点滴中心

第 11 章：慢性难治性痛风市场 - 按配销通路

  • 概述
    • 按配销通路分類的细分市场份额分析
    • 医院药房
    • 专业药房
    • 零售

第 12 章：慢性难治性痛风市场 - 按地区划分

  • 介绍
    • 按地区分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美慢性难治性痛风主要製造商
    • 北美市场规模及预测（按国家/地区）
    • 北美市场规模及预测（按治疗类别）
    • 北美市场规模及预测（按给药途径）
    • 北美市场规模及预测（按疾病负担）
    • 北美市场规模与预测，按合併症概况
    • 北美市场规模与预测，按护理环境
    • 北美市场规模及预测（按配销通路）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲慢性难治性痛风主要製造商
    • 欧洲市场规模及预测（按国家/地区）
    • 欧洲市场规模及预测（依治疗类别）
    • 欧洲市场规模及预测（依管理途径）
    • 欧洲市场规模及预测（依疾病负担）
    • 欧洲市场规模与预测，按合併症概况
    • 欧洲市场规模与预测，按护理环境
    • 欧洲市场规模及预测（按配销通路）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区（APAC）
    • 概述
    • 亚太地区慢性难治性痛风主要製造商
    • 亚太市场规模及预测（按国家/地区）
    • 亚太市场规模及预测（依治疗类别）
    • 亚太地区市场规模及预测（依给药途径）
    • 亚太市场规模及预测（依疾病负担）
    • 亚太市场规模及预测（依合併症情形）
    • 亚太市场规模及预测（依护理环境）
    • 亚太市场规模及预测（按配销通路）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲慢性难治性痛风主要製造商
    • 拉丁美洲市场规模及预测（按国家/地区）
    • 拉丁美洲市场规模及预测（依治疗类别）
    • 拉丁美洲市场规模及预测（按给药途径）
    • 拉丁美洲市场规模及预测（按疾病负担）
    • 拉丁美洲市场规模及预测（依合併症情形）
    • 拉丁美洲市场规模及预测（按护理环境）
    • 拉丁美洲市场规模及预测（按配销通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲慢性难治性痛风主要製造商
    • 中东和非洲市场规模及预测（按国家/地区）
    • 中东和非洲市场规模及预测（按治疗类别）
    • 中东和非洲市场规模及预测（按管理途径）
    • 中东和非洲市场规模及预测（按疾病负担）
    • 中东及非洲市场规模及预测（依合併症情形）
    • 中东和非洲市场规模及预测（按护理环境）
    • 中东和非洲市场规模及预测（按配销通路）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 其余地区

第 13 章：关键供应商分析-慢性难治性痛风产业

  • 竞争仪錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司简介
    • LG Chem
    • Jiangsu Hengrui Pharmaceuticals
    • JW Group / Simcere
    • Selecta / Cartesian Therapeutics
    • Sobi (Swedish Orphan Biovitrum)
    • Teijin America
    • InventisBio
    • Arthrosi Therapeutics
    • Shanton Pharma
    • Atom Bioscience
    • Horizon Therapeutics / Amgen
    • Nippon Chemiphar
    • Protalix BioTherapeutics
    • Arrowhead Pharmaceuticals
    • Hinova Pharmaceuticals
    • TaiwanJ Pharmaceuticals
    • Cartesian Therapeutics
    • Amgen
    • Takeda Pharmaceutical Company
    • AstraZeneca
    • Others

第 14 章：360 度分析师视角

第 15 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV5677

Chronic refractory gout market size was valued at US$ 1,804.25 Million in 2024, expanding at a CAGR of 10.23% from 2025 to 2032.

Chronic refractory gout is a severe form of gout in which patients do not respond adequately to standard urate-lowering therapies or cannot tolerate them. It is characterized by persistently high uric acid levels, frequent painful flares, and tophi formation that can damage joints and surrounding tissues. This condition often requires advanced treatments, such as uricase-based therapies or biologics, along with comprehensive management of comorbidities to reduce complications and improve quality of life.

Chronic Refractory Gout Market- Market Dynamics

Increasing burden of gouts across the globe to propel market demand

The rising global burden of gout is driving demand for advanced treatment options. In 2020, an estimated 55.8 million people worldwide were living with gout. Obesity and kidney dysfunction are major contributors to disability from the disease, with high body mass index accounting for 34.3% of years lived with disability (YLDs) due to gout, and kidney dysfunction contributing 11.8%. However, underdiagnosis of these comorbidities often delays appropriate treatment.

In the United States, the Centers for Disease Control and Prevention (CDC) reports that more than 1 in 7 adults have chronic kidney disease. On the positive side, lifestyle interventions targeting obesity can significantly reduce gout severity and progression. Additionally, improving chronic kidney disease (CKD) detection in gout patients could enhance treatment outcomes and help address one of the key underlying drivers of refractory cases.

Chronic Refractory Gout Market- Segmentation Analysis:

The Global Chronic Refractory Gout Market is segmented on the basis of Therapy Class, Route of Administration, Disease Burden, Comorbidity Profile, Propulsion, Distribution Channel, and Region.

The market is divided into four categories based on Therapy Class: uricase therapies, IL-1 inhibitors, adjunct anti-inflammatories, and next-generation small molecules. The uricase therapies segment is expected to hold the major market share during the forecast period. This dominance is driven by their unique ability to rapidly and effectively lower serum uric acid levels in patients unresponsive to conventional treatments.

The market is divided into two categories based on Comorbidity Profile: renal impairment and cardiovascular/metabolic conditions. Among these, the renal impairment segment is expected to capture the major market share. Chronic kidney disease is a frequent complication in gout patients, limiting the use of traditional urate-lowering drugs and creating higher reliance on advanced therapies like uricase-based treatments. Renal impairment poses the greatest therapeutic challenge, driving stronger demand for specialized and effective treatment options in this patient group.

Chronic Refractory Gout Market- Geographical Insights

North America cancer biopsy market dominated the global market, and a similar trend is observed in the chronic refractory gout segment due to high disease burden and strong healthcare infrastructure. According to the U.S. Centers for Disease Control and Prevention (CDC), nearly 9.2 million adults in the United States suffer from gout, representing about 3.9% of the adult population.

A significant proportion of these cases develop into chronic and treatment-resistant forms, driving the demand for advanced therapies such as pegloticase. The U.S. Food and Drug Administration (FDA) has prioritized approvals of biologics and novel urate-lowering drugs to address unmet needs in refractory cases. In Europe, the prevalence is also notable, with the UK's National Health Service (NHS) reporting a sharp rise in gout-related hospital admissions over the past decade. Meanwhile, in Asia Pacific, Japan's Ministry of Health and Welfare identifies gout as a growing concern linked to lifestyle diseases, further expanding treatment demand.

Chronic Refractory Gout Market- Competitive Landscape:

Rising prevalence of uncontrolled gout cases is encouraging companies to refine treatment strategies. Competitors are focusing on developing biologics and uricase-based therapies with improved safety and longer durability of response. Many are exploring combination regimens with immunomodulators to reduce antibody formation and enhance effectiveness. Partnerships with research institutes, specialty clinics, and payers aim to expand patient access. In parallel, firms are investing in patient-support programs, infusion services, and digital monitoring tools to strengthen adherence and improve long-term treatment outcomes.

Recent Development:

In March 2025, Shanton Pharma announced positive Phase 2b results for SAP-001 in refractory gout patients, showing nearly 100% target achievement versus 10% on conventional therapy, with sustained effects, strong efficacy, and excellent safety across six months of treatment.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CHRONIC REFRACTORY GOUT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • LG Chem
  • Jiangsu Hengrui Pharmaceuticals
  • JW Group / Simcere
  • Selecta / Cartesian Therapeutics
  • Sobi (Swedish Orphan Biovitrum)
  • Teijin America
  • InventisBio
  • Arthrosi Therapeutics
  • Shanton Pharma
  • Atom Bioscience
  • Horizon Therapeutics / Amgen
  • Nippon Chemiphar
  • Protalix BioTherapeutics
  • Arrowhead Pharmaceuticals
  • Hinova Pharmaceuticals
  • TaiwanJ Pharmaceuticals
  • Cartesian Therapeutics
  • Amgen
  • Takeda Pharmaceutical Company
  • AstraZeneca
  • Others

GLOBAL CHRONIC REFRACTORY GOUT MARKET, BY THERAPY CLASS- MARKET ANALYSIS, 2019 - 2032

  • Uricase Therapies
  • IL-1 inhibitors
  • Adjunct Anti-inflammatories
  • Next-generation Small Molecules

GLOBAL CHRONIC REFRACTORY GOUT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Intravenous
  • Subcutaneous
  • Oral

GLOBAL CHRONIC REFRACTORY GOUT MARKET, BY DISEASE BURDEN- MARKET ANALYSIS, 2019 - 2032

  • Tophaceous CRG
  • Frequent Flares
  • Erosive/structural damage

GLOBAL CHRONIC REFRACTORY GOUT MARKET, BY COMORBIDITY PROFILE- MARKET ANALYSIS, 2019 - 2032

  • Renal Impairment
  • Cardiovascular/Metabolic Conditions

GLOBAL CHRONIC REFRACTORY GOUT MARKET, BY CARE SETTING- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Specialty Rheumatology Clinics
  • Infusion Centers

GLOBAL CHRONIC REFRACTORY GOUT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Specialty Pharmacies
  • Retail

GLOBAL CHRONIC REFRACTORY GOUT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Chronic Refractory Gout Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Chronic Refractory Gout Market Snippet by Therapy Class
    • 2.1.2. Chronic Refractory Gout Market Snippet by Route of Administration
    • 2.1.3. Chronic Refractory Gout Market Snippet by Disease Burden
    • 2.1.4. Chronic Refractory Gout Market Snippet by Comorbidity Profile
    • 2.1.5. Chronic Refractory Gout Market Snippet by Care Setting
    • 2.1.6. Chronic Refractory Gout Market Snippet by Distribution Channel
    • 2.1.7. Chronic Refractory Gout Market Snippet by Country
    • 2.1.8. Chronic Refractory Gout Market Snippet by Region
  • 2.2. Competitive Insights

3. Chronic Refractory Gout Key Market Trends

  • 3.1. Chronic Refractory Gout Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Chronic Refractory Gout Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Chronic Refractory Gout Market Opportunities
  • 3.4. Chronic Refractory Gout Market Future Trends

4. Chronic Refractory Gout Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Chronic Refractory Gout Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Chronic Refractory Gout Market Landscape

  • 6.1. Chronic Refractory Gout Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Chronic Refractory Gout Market - By Therapy Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Therapy Class, 2023 & 2032 (%)
      • 7.1.1.1. Uricase Therapies
      • 7.1.1.2. IL-1 Inhibitors
      • 7.1.1.3. Adjunct anti-inflammatories
      • 7.1.1.4. Next-generation Small Molecules

8. Chronic Refractory Gout Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 8.1.2. Intravenous
    • 8.1.3. Subcutaneous
    • 8.1.4. Oral

Chronic Refractory Gout Market - By Disease Burden

  • 8.2. Overview
    • 8.2.1. Segment Share Analysis, By Disease Burden, 2023 & 2032 (%)
    • 8.2.2. Tophaceous CRG
    • 8.2.3. Frequent Flares
    • 8.2.4. Erosive/Structural Damage

9. Chronic Refractory Gout Market - By Comorbidity Profile

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Comorbidity Profile, 2023 & 2032 (%)
    • 9.1.2. Renal Impairment
    • 9.1.3. Cardiovascular/Metabolic Conditions

10. Chronic Refractory Gout Market - By Care Setting

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Care Setting, 2023 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Specialty Rheumatology Clinics
    • 10.1.4. Infusion Centers

11. Chronic Refractory Gout Market - By Distribution Channel

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 11.1.2. Hospital Pharmacies
    • 11.1.3. Specialty Pharmacies
    • 11.1.4. Retail

12. Chronic Refractory Gout Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Chronic Refractory Gout Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
    • 12.2.9. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.10. U.S.
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. U.S. Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.2.10.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.10.5. U.S. Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.2.10.6. U.S. Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.2.10.7. U.S. Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.2.10.8. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.2.10.9.
    • 12.2.11. Canada
      • 12.2.11.1. Overview
      • 12.2.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.11.3. Canada Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.2.11.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.11.5. Canada Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.2.11.6. Canada Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.2.11.7. Canada Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.2.11.8. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.2.11.9.
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Chronic Refractory Gout Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
    • 12.3.9. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.10. Germany
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. Germany Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.3.10.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.10.5. Germany Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.3.10.6. Germany Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.3.10.7. Germany Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.3.10.8. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.11. Italy
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. Italy Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.3.11.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.11.5. Italy Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.3.11.6. Italy Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.3.11.7. Italy Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.3.11.8. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.12. United Kingdom
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. United Kingdom Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.3.12.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.12.5. United Kingdom Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.3.12.6. United Kingdom Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.3.12.7. United Kingdom Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.3.12.8. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.13. France
      • 12.3.13.1. Overview
      • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.3. France Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.3.13.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.13.5. France Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.3.13.6. France Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.3.13.7. France Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.3.13.8. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.14. Russia
      • 12.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.2. Russia Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.3.14.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.14.4. Russia Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.3.14.5. Russia Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.3.14.6. Russia Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.3.14.7. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.15. Netherlands
      • 12.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.2. Netherlands Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.3.15.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Netherlands Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Netherlands Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Netherlands Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.3.15.7. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.16. Sweden
      • 12.3.16.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.2. Sweden Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.3.16.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Sweden Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Sweden Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Sweden Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.3.16.7. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.17. Poland
      • 12.3.17.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.2. Poland Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.3.17.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Poland Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Poland Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Poland Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.18. Rest of Europe
      • 12.3.18.1. Overview
      • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.18.3. Rest of the Europe Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.3.18.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.18.5. Rest of the Europe Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.3.18.6. Rest of the Europe Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.3.18.7. Rest of the Europe Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.3.18.8. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Chronic Refractory Gout Key Manufacturers in Asia Pacific
    • 12.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. Asia Pacific Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
    • 12.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.4.6. Asia Pacific Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
    • 12.4.7. Asia Pacific Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
    • 12.4.8. Asia Pacific Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
    • 12.4.9. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.10. India
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. India Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.4.10.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.10.5. India Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.4.10.6. India Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.4.10.7. India Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.4.10.8. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.11. China
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. China Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.4.11.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.11.5. China Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.4.11.6. China Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.4.11.7. China Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.4.11.8. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.12. Japan
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. Japan Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.4.12.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.12.5. Japan Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.4.12.6. Japan Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.4.12.7. Japan Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.4.12.8. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.13. South Korea
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. South Korea Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.4.13.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.13.5. South Korea Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.4.13.6. South Korea Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.4.13.7. South Korea Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.4.13.8. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.14. Australia
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Australia Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Australia Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Australia Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Australia Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.4.14.8. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.15. Thailand
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Thailand Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Thailand Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Thailand Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Thailand Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.4.15.8. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.16. Indonesia
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Indonesia Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Indonesia Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Indonesia Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Indonesia Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.4.16.8. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.17. Philippines
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Philippines Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Philippines Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Philippines Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Philippines Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.4.17.8. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.18. Rest of APAC
      • 12.4.18.1. Overview
      • 12.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.18.3. Rest of APAC Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.4.18.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.18.5. Rest of APAC Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.4.18.6. Rest of APAC Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.4.18.7. Rest of APAC Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.4.18.8. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.5. Latin America
    • 12.5.1. Overview
    • 12.5.2. Chronic Refractory Gout Key Manufacturers in Latin America
    • 12.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. Latin America Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
    • 12.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.5.6. Latin America Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
    • 12.5.7. Latin America Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
    • 12.5.8. Latin America Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
    • 12.5.9. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.10. Brazil
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Brazil Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Brazil Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Brazil Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Brazil Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.5.10.8. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.11. Mexico
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Mexico Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Mexico Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Mexico Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Mexico Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.5.11.8. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.12. Argentina
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Argentina Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Argentina Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Argentina Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Argentina Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.5.12.8. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.13. Colombia
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Colombia Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Colombia Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Colombia Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Colombia Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.5.13.8. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.14. Rest of LATAM
      • 12.5.14.1. Overview
      • 12.5.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.14.3. Rest of LATAM Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.5.14.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.14.5. Rest of LATAM Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.5.14.6. Rest of LATAM Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.5.14.7. Rest of LATAM Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.5.14.8. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Chronic Refractory Gout Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
    • 12.6.9. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.10. Saudi Arabia
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. Saudi Arabia Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.6.10.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.10.5. Saudi Arabia Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.6.10.6. Saudi Arabia Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.6.10.7. Saudi Arabia Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.6.10.8. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.11. United Arab Emirates
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. United Arab Emirates Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.6.11.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.11.5. United Arab Emirates Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.6.11.6. United Arab Emirates Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.6.11.7. United Arab Emirates Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.6.11.8. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.12. Israel
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Israel Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Israel Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Israel Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Israel Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.6.12.8. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.13. Turkey
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Turkey Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Turkey Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Turkey Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Turkey Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.6.13.8. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.14. Algeria
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Algeria Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Algeria Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Algeria Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Algeria Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.6.14.8. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.15. Egypt
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Egypt Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Egypt Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Egypt Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Egypt Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.6.15.8. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.16. Rest of MEA
      • 12.6.16.1. Overview
      • 12.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.16.3. Rest of MEA Market Size and Forecast, By Therapy Class, 2019 - 2032 (US$ Million)
      • 12.6.16.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.16.5. Rest of MEA Market Size and Forecast, By Disease Burden, 2019 - 2032 (US$ Million)
      • 12.6.16.6. Rest of MEA Market Size and Forecast, By Comorbidity Profile, 2019 - 2032 (US$ Million)
      • 12.6.16.7. Rest of MEA Market Size and Forecast, By Care Setting, 2019 - 2032 (US$ Million)
      • 12.6.16.8. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Chronic Refractory Gout Industry

  • 13.1. Competitive Dashboard
    • 13.1.1. Competitive Benchmarking
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. LG Chem
    • 13.2.2. Jiangsu Hengrui Pharmaceuticals
    • 13.2.3. JW Group / Simcere
    • 13.2.4. Selecta / Cartesian Therapeutics
    • 13.2.5. Sobi (Swedish Orphan Biovitrum)
    • 13.2.6. Teijin America
    • 13.2.7. InventisBio
    • 13.2.8. Arthrosi Therapeutics
    • 13.2.9. Shanton Pharma
    • 13.2.10. Atom Bioscience
    • 13.2.11. Horizon Therapeutics / Amgen
    • 13.2.12. Nippon Chemiphar
    • 13.2.13. Protalix BioTherapeutics
    • 13.2.14. Arrowhead Pharmaceuticals
    • 13.2.15. Hinova Pharmaceuticals
    • 13.2.16. TaiwanJ Pharmaceuticals
    • 13.2.17. Cartesian Therapeutics
    • 13.2.18. Amgen
    • 13.2.19. Takeda Pharmaceutical Company
    • 13.2.20. AstraZeneca
    • 13.2.21. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us